Journal home
Advance online publication
Current issue
Archive
Press releases
Supplements
Focuses
Guide to authors
Online submissionOnline submission
For referees
Free online issue
Contact the journal
Subscribe
Advertising
work@npg
Reprints and permissions
About this site
For librarians
 
NPG Resources
Nature
Nature Reviews
Nature Immunology
Nature Cell Biology
Nature Genetics
news@nature.com
Nature Conferences
Dissect Medicine
NPG Subject areas
Biotechnology
Cancer
Chemistry
Clinical Medicine
Dentistry
Development
Drug Discovery
Earth Sciences
Evolution & Ecology
Genetics
Immunology
Materials Science
Medical Research
Microbiology
Molecular Cell Biology
Neuroscience
Pharmacology
Physics
Browse all publications
Commentary
Nature Medicine  3, 136 - 143 (1997)
doi:10.1038/nm0297-136

Clinical investigators as critical determinants in pharmaceutical innovation

Christopher R. Flowers1 & Kenneth L. Melmon2

  1Research Assistant, Divisions of Medical Information Sciences and Clinical Pharmacology, Stanford University School of Medicine, Stanford, California 94305, USA

  2Associate Dean for Postgraduate Medical Education and Professor of Medicine and Molecular Pharmacology, Stanford University School of Medicine, Stanford, California 94305, USA

Clinical investigators perform a critical role in the process of drug development that is often overlooked by industry.

REFERENCES
  1. Lis, Y. & Walker, S.R. Novel medicines marketed in the UK (1960−87). Br. J. Clin. Pharmacol. 28, 33−343 (1989).
  2. DiMasi, J.A., Seibring, M.A. & Lasagna, L. New drug development in the United States from 1963 to 1992. Clin. Pharmacol. Ther. 55, 609−22 (1994). | PubMed  | ISI | ChemPort |
  3. DiMasi, J.A., Hansen, R.W., Grabowski, H.G. & Lasagna, L. Cost innovation in the pharmaceutical industry [see comments]. J. Health Econ. 10, 107−42 (1991). | Article | PubMed  | ISI | ChemPort |
  4. DiMasi, J.A., A.Risks, regulation, and rewards in new drug development in the United States. Regul. Toxicol. Pharmacol. 19, 228−35 (1994). | Article | PubMed  | ISI | ChemPort |
  5. DiMasi, J.A., Bryant, N.R. & Lasagna, L. New drug development in the United States from 1963 to 1990. Clin. Pharmacol. Ther. 50, 471−86 (1991). | PubMed  | ISI | ChemPort |
  6. Prentis, R.A., Lis, Y. & Walker, S.R. Pharmaceutical innovation by the seven UK-owned pharmaceutical companies (1964-1985). Br. J. Clin. Pharmacol. 25, 387−396 (1988). | PubMed  | ISI | ChemPort |
  7. Fischer, W.A. & Rosen, B. The search for the latent information star. R & D Manage. 12, 61−66 (1982).
  8. Armstrong, J.M. & Hicks, P.E. An industrial approach to drug discovery: A pharmacologist's eye view. Clin. Exp. Pharmacol. Physiol. 19, 51−56 (1992). | PubMed  | ISI | ChemPort |
  9. Lee, S. & Treacy, M.E. Information technology impacts on innovation. R&D Manage. 18, 257−271 (1988).
  10. Globe, S., Levy, G.W. & Schwartz, C.M. Key factors and events in the innovation process. Res. Manage. (Jul.), 8−15 (1973).
  11. Hitchings, G.H., Elion, G.B., Falco, E.A., Russell, P.B. & VanderWerff, H. Studies on analogs of purines and pyrimidines. Ann. N. Y. Acad. Sci. 52, 1318−1335 (1950). | ISI | ChemPort |
  12. Hitchings, G., Jr. Nobel lecture in physiology or medicine — 1988. Selective inhibitors of dihydrofolate reductase. In Vitro Cell Dev. Biol. 25, 303−10 (1989). | PubMed  | ISI | ChemPort |
  13. Elion, G.B., Callahan, S.W., Hitchings, G.H., Rundles, R.W. & Lazlo, J., Experimental, clinical, and metabolic studies of thiopurines. Cancer Chemother. Rep. 16, 197−202 (1962). | PubMed  |
  14. Elion, G.B., Callahan, S., Nathan, H., Bieber, S., Rundles, R.W. & Hitchings, G.H. Potentiation by inhibition of drug degradation: 6-Substituted purines and xanthine oxidase. Biochem. Pharmacol. 12, 85−93 (1963). | Article | ISI | ChemPort |
  15. Rosenberg, N. Critical issues in science policy research. Sci. Pub. Policy 18, 335−346 (1991).
  16. Rose, N.R., Barron, A.L., Crane, L.R. & Menna, J.H. Microbiology: Basic Principles and Clinical Applications. 1−647 (Macmillan, New York, 1983).
  17. Bynum, W.F. & Porter, R. Companion Encyclopedia of the History of Medicine. (Routledge, New York, 1993).
  18. Myrvik, Q.N. & Weiser, R.S. Fundamentals of Immunology. 1−510 (Lea & Febiger, Philadelphia, 1984).
  19. Burchenal, J.H. et al. Preliminary studies on the effect of 2,6-diaminopurine on transplanted mouse leukemia. Cancer 2, 119−120 (1949). | ISI | ChemPort |
  20. Burchenal, J.H. et al. The effects of folic acid antagonists and 2,6-diaminopurine on neoplastic disease: With special reference to acute leukemia. Cancer (Philadelphia) 4, 519−569 (1951).
  21. Burchenal, J.H., Burchenal, J.R., Kushida, M.N., Johnston, S.F. & Williams, B.S. Studies on the chemotherapy of leukemia. Cancer (Philadelphia) 2, 113−118 (1949). | ChemPort |
  22. Nathan, H.C., Bieber, S., Elion, G.B. & Hitchings, G.H. Detection of agents which interfere with the immune response. Proc. Soc. Exp. Biol. Med. 107, 796−799 (1961). | PubMed  | ISI | ChemPort |
  23. Calne, R.Y., Alexandre, G.P.J. & Murray, J.E. A study of the effects of drugs in prolonging survival of homologous renal transplants in dogs. Ann. N. Y. Acad. Sci. 99, 743−761 (1962). | PubMed  | ISI | ChemPort |
  24. Schwartz, R., Stack, J. & Dameshek, W. Effect of 6-mercaptopurine on antibody production. Proc. Soc. Exp. Biol. Med. 99, 164−167 (1958). | PubMed  | ISI | ChemPort |
  25. Schwartz, R. & Dameshek, W. Drug-induced immunological tolerance. Nature 183, 1682−1683 (1959). | PubMed  | ISI | ChemPort |
  26. Calne, R.Y. The rejection of renal homografts: Inhibition in dogs by 6-mercaptopurine. Lancet i, 417−418 (1960). | Article | ChemPort |
  27. Elion, G.B., Mueller, S. & Hitchings, G.H. Studies on condensed pyrimidine systems. XXI. The isolation of synthesis of 6-mercapto-2,8-purinediol (6-thiouric acid). J. Am. Chem. Soc. 81, 3042−3045 (1959). | ISI | ChemPort |
  28. Hitchings, G.H. & Elion, G.B. Layer on layer: the Bruce F. Cain Memorial Award Lecture. Cancer Res. 45, 2415−2420 (1985). | PubMed  | ISI | ChemPort |
  29. Elion, G.B. Nobel lecture in physiology or medicine — 1988. The purine path to chemotherapy. In Vitro Cell Dev. Biol. 25, 321−30 (1989). | PubMed  | ISI | ChemPort |
  30. Rundles, R.W., Metz, E.N. & Silberman, H.R. Allopurinol in the treatment of gout. Ann. Intern. Med. 64, 229−257 (1966). | PubMed  | ISI | ChemPort |
  31. Rundles, R.W., Wyngaarden, J.B., Hitchings, G.H., Elion, G.B. & Silberman, H.R. Effects of a xanthine oxidase inhibitor on thiopurine metabolism, hyperuricemia, and gout. Trans. Assoc. Am. Physicians 76, 126 (1963). | ChemPort |
  32. Hamilton, L. & Elion, G.B. The fate of 6-mercaptopurine in man. Ann. N.Y. Acad. Sci. 60, 304−314 (1954). | PubMed  | ChemPort |
  33. Elion, G.B., Rideout, J.L., deMiranda, P., Collins, P., & Bauer, D.J., Biological activities of some purine arabinosides. Biological activities of some purine arabinosides. Ann. N.Y. Acad. Sci. 255, 468−480 (1975). | PubMed  | ChemPort |
  34. Kaufman, H.E., Nesburn, A.B. & Maloney, E.D., lUdR therapy for herpes simplex. Arch. Ophthalmol. 67, 583 (1962).
  35. Kaufman, H.E. & Heidelberger, C. Therapeutic antiviral action of 5-trifluoromethyl-2'-deoxyuridine in herpes simplex keratitis. Science 145, 585 (1964). | PubMed  | ChemPort |
  36. Heidelberg, C. et al. Fluorinated pyrimidines, a new class of tumor-inhibitory compounds. Nature 179, 663−666 (1957). | PubMed  | ISI | ChemPort |
  37. Ellison, R.R. et al. Arabinosytcytosine: A useful agent in the treatment of acute leukemia in adults. Blood 32, 507−523 (1968). | PubMed  | ISI | ChemPort |
  38. Talley, R. & Vaitkevicius, V.K. Megaloblastosis produced by cytosine antagonist, 1 —D-arabinofuranocylcytosine. Blood 21, 352−362 (1963). | PubMed  | ISI | ChemPort |
  39. Elion, G.B., scovery, mechanism of action, and selectivity. J. Med. virol. 1, 2−6 (1993).
  40. Thompson, R.L. et al. The effects of antagonists on the multiplication of vaccinia virus in vitro. Science 110, 454 (1949).
  41. Thompson, R.L., Price, M.L., Menton, S.A., Elion, G.B. & Hitchings, G.H. Effects of purine derivatives an analogs on multiplication of the vaccinia virus. J. Immunol. 65, 529−534 (1950). | PubMed  | ISI | ChemPort |
  42. Schabel, F.M.J. The antiviral activity of 9-beta-D-arabinofuranosyladenine (ARA-A). Chemotherapy 13, 321−338 (1968). | PubMed  | ISI | ChemPort |
  43. Schaeffer, H.J. et al. 9-(2-Hydroxyethoxymethyl) guanine activity against viruses of the herpes group. Nature 272, 583−5 (1978). | PubMed  | ISI | ChemPort |
  44. Elion, G.B. The purine path to chemotherapy. Science 244, 41−7 (1989). | PubMed  | ISI | ChemPort |
  45. Verheyden, J.P.H., Ganciclovir. in Chronicles of Drug Discovery (ed. Lednicer, D.) 299−326 (Wiley, New York, 1993). | ChemPort |
  46. Crumpacker, C., Marlowe, S., Zhang, J.L., Abrams, S. & Watkins, P. Treatment of cytomegalovirus pneumonia. Rev. Infect. Dis. 10, S53846 (1988). | PubMed  |
  47. Crumpacker, C.S. Treatment of opportunistic viral infections. AIDS 2, S191−S193 (1988). | ChemPort |
  48. Crumpacker, C. Molecular targets of antiviral therapy. N. Engl. J. Med. 321, 163−72 (1989). | PubMed  | ISI | ChemPort |
  49. Calne, R.Y. et al. Cyclosporin A in clinical kidney grafting from cadaver donors. Proc. Eur. Dial. Transplant. Assoc. 16, 305−9 (1979). | PubMed  | ChemPort |
  50. Calne, R.Y., Cyclosporin. Nephron 26, 57−63 (1980). | PubMed  | ISI | ChemPort |
  51. Kostakis, A.J., White, D.J. & Calne, R.Y. Prolongation of rat heart allograft survival by Cyclosporin A. IRCS (Int. Res. Common. Syst.) J. Med. Sci. 5, 280 (1977). | ChemPort |
  52. Kostakis, A.J., White, D.J. & Calne, R.Y. Toxic effects in the use of Cyclosporin A in alcoholic solution as an immunosuppressant of rat heart allografts. IRCS (Int. Res. Commun. Syst.) J. Med. Sci. 5, 243 (1977).
  53. Allen, T.J. Managing the Flow of Scientific and Technological Information (MIT Press, Cambridge, MA, 1966).
  54. Allen, T.J. Managing the Flow of Technology (MIT Press, Cambridge, MA, 1984).
  55. Mohr, L.B. Determinants of innovation in organization. Am. Polit. Sci. Rev. 63, 111−126 (1969). | ISI |
  56. Pierce, J.L. & Delbeq, A.L. Organization structure, individual attitudes, and innovation. Acad. Manage. Rev. 2, 27−37 (1977).
  57. Gerwin, D. Control and evaluation in the innovation process: The case of flexible manufacturing systems. IEEE (Inst. Electr. Electron. Eng.) Trans. Eng. Manage. EM−28, 62−70 (1981). | ISI |
  58. Galbraith, J.R. Designing the innovating organization. Organ. Dyn. (Winter), 5−25 (1982). | Article | PubMed  |
  59. Damanpour, F. & Evan, W.M. Organizational innovation and preference: The problem of organizational lag. Administr. Sci. Q. 29, 392−409 (1984). | ISI |
  60. Chakrabati, A.K. The role of champion in product innovation. Calif. Manage. Rev. 17, 58−62 (1974).
  61. Chakrabati, A.K. & Hauschildt, J. The division of labour in innovation management. R&D Manage. 19, 161−171 (1989).
  62. Pearson, R.A. Innovation strategy. Technovation 10, 185−192 (1990). | Article | ISI |
  63. Thier, S.O. The social and scientific value of biomedical research. J. R. Coll. Physicians Land. 28, 541−543 (1994). | ChemPort |
  64. Kelley, W.N. & Randolph, M.A. (eds.) in Careers in Clinical Research: Obstacles and Opportunities. 1−21 (National Academy Press, Washington, DC, 1994).
  65. Henderson, R. Managing innovation in the information age. Harvard Bus. Rev. 72, 100−105 (1994). | ISI |
  66. Henderson, R.M. & Clark, K.B. Architectural innovation: The reconfiguring of existing product technologies and the failure of established firms. Administr. Sci. Q. 35, 9−30 (1990). | ISI |
  67. Elion, G.B., Hitchings, G.H. & VanderWerff, H. Antagonists of nucleic acid derivatives. VI. Purines. J. Biol. Chem. 192, 505−518 (1951). | PubMed  | ISI | ChemPort |
  68. Clarke, D.A. et al. 6-mercaptopurine: Effects in mouse sarcoma 180 and in normal animals. Cancer Res. 13, 593−604 (1953). | PubMed  | ISI | ChemPort |
  69. Burchenal, J.H. et al. Clinical evaluation of a new antimetabolite, 6-mercaptopurine, in the treatment of leukemia and allied diseases. Blood: J. Hematol. 8, 965−999 (1953). | ChemPort |
  70. Murray, J.E., Merrill, J.P., Harrison, J.H., Wilson, R.E. & Dammin, G.J. Prolonged survival of human-kidney homografts by immunosuppressive drug therapy. N. Engl. J. Med. 268, 1315−1323 (1963). | PubMed  | ISI | ChemPort |
  71. Hitchings, G.H., Elion, G.B., VanderWerff, H. & Falco, E.A. Pyrimidine derivatives as antagonists of pteroylglutamic acid. J. Biol. Chem. 174, 765−766 (1948). | ISI | ChemPort |
  72. Elion, G.B. & Hitchings, G.H. Antagonists of nucleic acid derivative. IV. Reversal studies with 2-aminopurine and 2,6-diaminopurine. J. Biol. Chem. 187, 511−521 (1950). | PubMed  | ISI | ChemPort |
  73. Hitchings, G.H., Elion, G.B., Falco, E.A., Sherwood, M.B. & VanderWerff, H. Antagonists of nucleic acid derivatives. I. The Lactobacillus easei model. J. Biol. Chem. 183, 1−8 (1950). | ISI | ChemPort |
  74. Elion, G.B., Callahan, S.W., Rundles, R.W. & Hitchings, G.H. Relationship between metabolic fates and antitumor activities of thiopurines. Cancer Res. 23, 1207−1217 (1963). | PubMed  | ISI | ChemPort |
  75. Yü, T.F., & Gutman, A.B., Effect of allopurinol (4-hydroxypyrazolo-(3,4-d)pyrimidine) on serum and urinary uric acid in primary and secondary gout. Am. J. Med. 37, 885−898 (1964). | Article | PubMed  | ISI |
  76. Elion, G.B. et al. Selectivity of action of an antiherpetic agent, 9-(2-hydroxy-ethoxymethyl)-guanine. Proc. Notl. Acad. Sci. USA 74, 5716−5720 (1977). | ChemPort |
  77. Verheyden, J.P. et al. Synthesis of certain 4'-substituted nucleosides. Ann. N. Y. Acad. Sci. 255, 151−65 (1975). | PubMed  | ISI | ChemPort |
  78. Verheyden, J. & Moffatt, J.G. 4'-Substituted nucleosides. I. Synthesis of 4'-methoxyuridine and related compounds. J. Am. Chem. Soc. 97, 4386−95 (1975). | PubMed  | ISI | ChemPort |
  79. Selby, P.J. et al. Parenteral acyclovir therapy for herpesvirus infections in man. Lancet 2, 1267−1270 (1979). | Article | PubMed  | ISI | ChemPort |
 Top
 Top
References
Previous | Next
Table of contents
Download PDFDownload PDF
Send to a friendSend to a friend
Save this linkSave this link

natureevents

References
Export citation
Export references
natureproducts

Search buyers guide:

 
ADVERTISEMENT
 
Nature Medicine
ISSN: 1078-8956
EISSN: 1546-170X
Journal home | Advance online publication | Current issue | Archive | Press releases | Supplements | Focuses | For authors | Online submission | For referees | Free online issue | About the journal | Contact the journal | Subscribe | Advertising | work@npg | Reprints and permissions | About this site | For librarians
Nature Publishing Group, publisher of Nature, and other science journals and reference works©1997 Nature Publishing Group | Privacy policy